Swedish Orphan Biovitrum AB (Sobi), a developer of drugs for rare diseases, has terminated discussions with an undisclosed party in relation to a possible takeover proposal for the company. Sobi announced the end of discussions on 8 June.
Allergy Therapeutics Plc, a UK-based specialty pharmaceutical company, has paid €3.8 million in cash for Alerpharma SA of Spain in order to increase its presence on the Spanish market for allergy therapies where it already has a subsidiary.
Abivax SAS, which is developing a compound that inhibits HIV replication, has announced plans to raise €43.6 million in an initial public offering on the Paris Euronext exchange, a figure that could rise to €57.7 million if an overallotment option is exercised.
The Netherlands-based cell therapy company Kiadis Pharma BV is planning an initial public offering (IPO) of its shares on the Euronext stock exchanges in Amsterdam and Brussels to finance the clinical development of a cell therapy that helps reconstitute the immune system after a bone marrow transplant.
The antibody developer ArGEN-X NV has joined forces with the dermatology expert LEO Pharma A/S to investigate an antibody therapeutic for the treatment of inflammation-related skin diseases.
Merck Serono has extended its reproductive health franchise to include rights to three in vitro fertilization (IVF) products developed by Genea Biomedx Ltd of Australia. The financial terms of the collaboration were not disclosed.
In a reversal of a recent trend, Boston-based PureTech Health Plc is planning to launch an initial public offering of shares on the London Stock Exchange with the intention of raising $160 million. In recent months, most life science IPOs have taken place in the US.
Circassia Pharmaceuticals Plc is raising £275 million on the London Stock Exchange following its initial public offering in March 2014 of £202 million. The developer of immunotherapies for allergies will use the proceeds to buy two other companies for an aggregate of up to £239 million.
Juno Therapeutics Inc has acquired Stage Cell Therapeutics GmbH, a privately-owned biotechnology company in Germany, in order gain access to research and manufacturing technologies and to a pipeline of clinical and preclinical assets.
Pfizer Inc has acquired a minority stake in privately-held AM-Pharma BV which has a Phase 2 product for acute kidney injury related to sepsis. The US company made an upfront payment of $87.5 million to AM-Pharma in early May for the stake, and also secured an exclusive option to buy the rest of the company.